ReviewAntibiotics (Basel, Switzerland)2013
Rifampicin Resistance: Fitness Costs and the Significance of Compensatory Evolution.
Review in Antibiotics (Basel, Switzerland), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 32 citations in OpenAlex.
- Synergistic activity of rifampicin and polymyxin B against intracellular Gram-negative ESKAPE pathogens involves bacterial membrane alterations and enhanced oxidative damages.Antimicrobial agents and chemotherapy · 2026Article
- Tracing the evolutionary dynamics of carbapenem-resistant Escherichia coli in recurrent and multi-site infections.Gut pathogens · 2025Article
- The Usefulness of the BD MAX MDR-TB Molecular Test in the Rapid Diagnosis of Multidrug-Resistant Tuberculosis.Pathogens (Basel, Switzerland) · 2025Article
- A plasmid with theMicrobiology (Reading, England) · 2025Article
- Performance of the BD MAX MDR-TB assay in a clinical setting and its impact on the clinical course of patients with pulmonary tuberculosis: a retrospective before-after study.Journal of Yeungnam medical science · 2024Article
- Phenotype versus genotype discordant rifampicin susceptibility testing in tuberculosis: implications for a diagnostic accuracy.Microbiology spectrum · 2024Article
- Antibiotic Resistance in Metal-Tolerant Microorganisms from Treatment Facilities.Antibiotics (Basel, Switzerland) · 2023Article
- Selection of Multi-Drug Targets against Drug-ResistantInternational journal of molecular sciences · 2023Article
- Genotypic Distribution and the Epidemiology of Multidrug Resistant Tuberculosis in Upper Northern Thailand.Antibiotics (Basel, Switzerland) · 2022Article
- Review
- Structural Design and Synthesis of Novel Cyclic Peptide Inhibitors TargetingLife (Basel, Switzerland) · 2022Article
- Review
- Reevaluating Rifampicin Breakpoint Concentrations for Mycobacterium tuberculosis Isolates with DisputedMicrobiology spectrum · 2022Article
- Article
- Article
- Genome-Based Analyses of Fitness Effects and Compensatory Changes Associated with Acquisition ofAntibiotics (Basel, Switzerland) · 2021Article
- Genomic and Transcriptomic Analysis of BovineFrontiers in veterinary science · 2021Article
- Inhibition of RNA Polymerase by Rifampicin and Rifamycin-Like Molecules.EcoSal Plus · 2020Article
- Genomic Analysis of Mycobacterium tuberculosis Isolates and Construction of a Beijing Lineage Reference Genome.Genome biology and evolution · 2020Article
- Characteristics of compensatory mutations in the rpoC gene and their association with compensated transmission of Mycobacterium tuberculosis.Frontiers of medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Seventy years after the introduction of antibiotic chemotherapy to treat tuberculosis, problems caused by drug-resistance in Mycobacterium tuberculosis have become greater than ever. The discovery and development of novel drugs and drug combination therapies will be critical to managing these problematic infections. However, to maintain effective therapy in the long-term and to avoid repeating the mistakes of the past, it is essential that we understand how resistance to antibiotics evolves in M. tuberculosis. Recent studies in genomics and genetics, employing both clinical isolates and model organisms, have revealed that resistance to the frontline anti-tuberculosis drug, rifampicin, is very strongly associated with the selection of fitness compensatory mutations in the different subunits of RNA polymerase. This mode of resistance evolution may also apply to other drugs, and knowledge of the rates and mechanisms could be used to design improved diagnostics and by tracking the evolution of infectious strains, to inform the optimization of therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.